Tìm theo
Omapatrilat
Thuốc Gốc
Small Molecule
CAS: 167305-00-2
CTHH: C19H24N2O4S2
PTK: 408.535
Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C19H24N2O4S2
Phân tử khối
408.535
Monoisotopic mass
408.117748646
InChI
InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13?,14-,15-,16-/m0/s1
InChI Key
InChIKey=LVRLSYPNFFBYCZ-JFKGFPBSSA-N
IUPAC Name
(7S,10aS)-5-oxo-4-[(2S)-3-phenyl-2-sulfanylpropanamido]-octahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
Traditional IUPAC Name
(7S,10aS)-5-oxo-4-[(2S)-3-phenyl-2-sulfanylpropanamido]-octahydropyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
SMILES
[H][C@]12CCC[C@H](N1C(=O)C(CCS2)NC(=O)[C@@H](S)CC1=CC=CC=C1)C(O)=O
Độ hòa tan
7.69e-02 g/l
logP
2.6
logS
-3.7
pKa (strongest acidic)
3.77
pKa (Strongest Basic)
-3.6
PSA
86.71 Å2
Refractivity
106.68 m3·mol-1
Polarizability
42.03 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
4
H Bond Donor Count
3
Physiological Charge
-1
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Omapatrilat is used to treat hypertension. Vasopeptidase inhibitor that simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). Omapatrilat lowers blood pressure by inhibiting the action of the angiotensin converting enzyme (ACE), which causes blood vessels to constrict. But unlike other drugs, omapatrilat also inhibits another enzyme known as neutral endopeptidase (NEP), which helps blood vessels relax. Omapatrilat demonstrated greater reduction in blood pressure than the ACE inhibitor lisinopril in individuals with salt-sensitive hypertension who typically do not respond well to ACE inhibitors.
Cơ Chế Tác Dụng : Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns. Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
Dược Động Học :
▧ Absorption :
The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.
▧ Metabolism :
Hepatic
Độc Tính : Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema
Chỉ Định : For the treatment of hypertension.
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Vanlev
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00886
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=126046
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=702772
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01970
ChemSpider
http://www.chemspider.com/Chemical-Structure.112074.html
Wikipedia
http://en.wikipedia.org/wiki/Omapatrilat
... loading
... loading